Sarepta Therapeutics (SRPT) Earnings Date, Estimates & Call Transcripts $123.29 -2.71 (-2.15%) (As of 11/1/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Sarepta Therapeutics Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 6After Market ClosesConfirmedActual EPS (Aug. 7) $0.07 Beat By $0.06 Consensus EPS (Aug. 7) $0.01 Sarepta Therapeutics posted Q2 2024 earnings on August 7, 2024, reporting an EPS of $0.07, which beat analysts' consensus estimates of $0.01 by $0.06. Quarterly revenue rose 38.9% year-over-year to $362.90 million, below the consensus estimate of $394.38 million. With a trailing EPS of $0.45 and a P/E Ratio of 273.98, Sarepta Therapeutics' earnings are expected to grow 599.32% next year, from $1.48 to $10.35 per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseSRPT Upcoming EarningsSarepta Therapeutics' next earnings date is scheduled for Wednesday, November 6, 2024, with a conference call scheduled for at 4:30 PM ET. Interested parties can register for or listen to the call. Skip Charts & View Estimated and Actual Earnings DataSRPT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SRPT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Sarepta Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$0.55$0.17-$0.23Q2 20244-$0.58$0.62-$0.04Q3 20244-$0.12$1.92$0.76Q4 20244$0.68$5.44$2.51FY 202415-$0.57$8.15$3.00Q1 20252$1.89$2.04$1.97Q2 20252$1.99$2.09$2.04Q3 20252$2.10$2.81$2.46Q4 20252$2.18$2.68$2.43FY 20258$8.16$9.62$8.89Q1 20261$2.80$2.80$2.80Q2 20261$3.32$3.32$3.32Q3 20261$3.31$3.31$3.31 Sarepta Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Confirmed)------- 8/7/2024Q2 2024$0.01$0.07+$0.06$0.07$394.38M$362.90M 5/1/2024Q1 2024-$0.11$0.73+$0.84$0.39$375.52M$413.50M 2/28/2024Q4 2023-$0.03$0.47+$0.50$0.47$387.18M$396.80M 11/1/2023Q3 2023-$1.63$0.37+$2.00-$0.46$285.33M$331.80M 8/2/2023Q2 2023-$1.89-$0.27+$1.62-$0.27$255.99M$261.20M 5/2/2023Q1 2023-$1.46-$0.97+$0.49$2.98$241.47M$253.50M Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now.2/28/2023Q4 2022-$1.28-$1.24+$0.04-$1.24$250.51M$258.43M 11/2/2022Q3 2022-$1.21-$2.94 -$1.73-$2.94$234.55M$230.30M Sarepta Therapeutics Earnings - Frequently Asked Questions When is Sarepta Therapeutics's earnings date? Sarepta Therapeutics has confirmed that its next quarterly earnings data will be published on Wednesday, November 6th, 2024. Learn more on SRPT's earnings history. Did Sarepta Therapeutics beat their earnings estimates last quarter? In the previous quarter, Sarepta Therapeutics (NASDAQ:SRPT) reported $0.07 earnings per share (EPS) to beat the analysts' consensus estimate of $0.01 by $0.06. Learn more on analysts' earnings estimate vs. SRPT's actual earnings. How can I listen to Sarepta Therapeutics's earnings conference call? The conference call for Sarepta Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Sarepta Therapeutics's conference call transcript? The conference call transcript for Sarepta Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Sarepta Therapeutics generate each year? Sarepta Therapeutics (NASDAQ:SRPT) has a recorded annual revenue of $1.24 billion. How much profit does Sarepta Therapeutics generate each year? Sarepta Therapeutics (NASDAQ:SRPT) has a recorded net income of -$535.98 million. SRPT has generated $0.45 earnings per share over the last four quarters. What is Sarepta Therapeutics's price-to-earnings ratio? Sarepta Therapeutics (NASDAQ:SRPT) has a trailing price-to-earnings ratio of 273.98 and a forward price-to-earnings ratio of 83.30. What is Sarepta Therapeutics's EPS forecast for next year? Sarepta Therapeutics's earnings are expected to grow from $1.48 per share to $10.35 per share in the next year, which is a 599.32% increase. ` More Earnings Resources from MarketBeat Related Companies JAZZ Earnings Date IONS Earnings Date PTCT Earnings Date ACAD Earnings Date WVE Earnings Date SLDB Earnings Date TAK Earnings Date BNTX Earnings Date BGNE Earnings Date MRNA Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. This page (NASDAQ:SRPT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Sarepta Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
